One of our Co-CEO, Iwamiya, spoke at an event hosted by The American Chamber of Commerce in Japan (ACCJ) and supported by the Life Science Innovation Network Japan (LINK-J).
Metcela Inc., a biotech startup specializing in fibroblast-based cell therapy, announces that the Japanese Patent Office (JPO) has issued Japanese Patent No. 6618066 to support the company’s technology of VCF (VCAM-1-positive Cardiac Fibroblast).
Metcela Inc., a biotech startup specializing in fibroblast-based cell therapy, announces that the company was selected for J-Startup 2019, a public-private joint initiative for supporting startup. Read more…